The stock of Lannett Company, Inc. (NYSE:LCI) is a huge mover today! The stock increased 6.02% or $1.3 during the last trading session, hitting $22.9. About 593,102 shares traded hands. Lannett Company, Inc. (NYSE:LCI) has risen 6.04% since April 22, 2016 and is uptrending. It has outperformed by 0.63% the S&P500.
The move comes after 9 months positive chart setup for the $861.30M company. It was reported on Nov, 25 by Barchart.com. We have $24.27 PT which if reached, will make NYSE:LCI worth $51.68M more.
Analysts await Lannett Company, Inc. (NYSE:LCI) to report earnings on February, 1. They expect $0.83 earnings per share, down 12.63% or $0.12 from last year’s $0.95 per share. LCI’s profit will be $31.22M for 6.90 P/E if the $0.83 EPS becomes a reality. After $0.77 actual earnings per share reported by Lannett Company, Inc. for the previous quarter, Wall Street now forecasts 7.79% EPS growth.
Lannett Company, Inc. (NYSE:LCI) Ratings Coverage
Out of 8 analysts covering Lannett (NYSE:LCI), 6 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 75% are positive. Lannett has been the topic of 20 analyst reports since July 21, 2015 according to StockzIntelligence Inc. The stock of Lannett Company, Inc. (NYSE:LCI) earned “Hold” rating by Craig Hallum on Thursday, November 5. As per Thursday, September 3, the company rating was maintained by Roth Capital. Roth Capital maintained Lannett Company, Inc. (NYSE:LCI) on Thursday, March 24 with “Buy” rating. Roth Capital maintained Lannett Company, Inc. (NYSE:LCI) rating on Friday, March 11. Roth Capital has “Buy” rating and $3 price target. On Wednesday, June 29 the stock rating was initiated by Deutsche Bank with “Hold”. The rating was maintained by Raymond James on Wednesday, August 24 with “Outperform”. The firm earned “Buy” rating on Wednesday, August 26 by Roth Capital. Craig Hallum maintained the shares of LCI in a report on Thursday, August 27 with “Buy” rating. Zacks upgraded the stock to “Strong-Buy” rating in Monday, September 7 report. The firm has “Buy” rating given on Thursday, February 4 by Craig Hallum.
According to Zacks Investment Research, “Lannett, Inc. manufactures and distributes pharmaceutical products sold under generic names and historically has manufactured and distributed pharmaceutical products sold under its trade or brand names. In addition, the Company contract manufactures and private labels pharmaceutical products for other companies.”
Insitutional Activity: The institutional sentiment increased to 1.36 in 2016 Q2. Its up 0.48, from 0.88 in 2016Q1. The ratio is positive, as 38 funds sold all Lannett Company, Inc. shares owned while 51 reduced positions. 27 funds bought stakes while 51 increased positions. They now own 27.61 million shares or 4.85% less from 29.01 million shares in 2016Q1.
Capital Fund Mngmt last reported 98,137 shares in the company. Hutchin Hill L P last reported 73,700 shares in the company. Prudential Inc holds 0% of its portfolio in Lannett Company, Inc. (NYSE:LCI) for 84,688 shares. National Bank & Trust Of America Corporation De owns 80,816 shares or 0% of their US portfolio. Tfs Ltd accumulated 20,535 shares or 0.09% of the stock. Macquarie Group holds 0% or 34,600 shares in its portfolio. Blackrock Incorporated has 7,517 shares for 0% of their US portfolio. Wfg Advsr Lp has 50 shares for 0% of their US portfolio. California Pub Employees Retirement accumulated 89,100 shares or 0% of the stock. Axa has 9,800 shares for 0% of their US portfolio. Dupont Capital Mngmt has 82,305 shares for 0.04% of their US portfolio. Zpr Mgmt last reported 7.51% of its portfolio in the stock. Charlemagne Capital Ltd last reported 6,323 shares in the company. D E Shaw & has 10,020 shares for 0% of their US portfolio. Alliancebernstein L P reported 43,450 shares or 0% of all its holdings.
Insider Transactions: Since August 31, 2016, the stock had 0 insider purchases, and 3 insider sales for $416,823 net activity. On Wednesday, August 31 the insider Landis G. Michael sold $226,716. Another trade for 1,478 shares valued at $50,119 was made by Maher James M. on Thursday, September 1.
More notable recent Lannett Company, Inc. (NYSE:LCI) news were published by: Prnewswire.com which released: “LCI LOSS ALERT: Rosen Law Firm Reminds Lannett Company, Inc. Investors of …” on November 22, 2016, also Businesswire.com with their article: “LANNETT INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn …” published on November 19, 2016, Globenewswire.com published: “SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Lannett …” on November 21, 2016. More interesting news about Lannett Company, Inc. (NYSE:LCI) were released by: Businesswire.com and their article: “IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action …” published on November 16, 2016 as well as Prnewswire.com‘s news article titled: “LANNETT NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered …” with publication date: November 14, 2016.
LCI Company Profile
Lannett Company, Inc., incorporated on December 3, 1991, develops, makes, markets and distributes generic versions of brand pharmaceutical products. The Firm makes and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc. As of June 30, 2016, the Company’s products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules. The Firm has additional products under development, which are orally administered solid oral-dosage products (tablet/capsule) or oral solutions, nasal, topicals or parentarels, as well as other dosage forms.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.